Mainz Biomed B.V.
Mainz Biomed B.V. (MYNZ) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mynz · stock forecast · 3 analysts (3M) · FMP · updated Mar 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Hold
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.33
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.33 | ↑ 0.09% |
1-day model range: $2.19–$2.48. Peak: $2.48 (+0.09%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MYNZ · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-25 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-11-21 | Cantor Fitzgerald | Downgrade ↓ | Overweight→Neutral |
| 2023-11-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-26 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-09-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-14 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-22 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-08-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-06-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Mainz Biomed B.V. (MYNZ) stock. Of the recent 17 rating actions, 0 were upgrades and 2 were downgrades. 3 analysts currently cover MYNZ.
Analyst Recommendation Trends
MYNZ analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 64.9% YoY
Revenue Next Year
$1M
↑ 5.0% YoY
EPS This Year
$-2.86
EPS Next Year
$-0.03
↓ 99.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast MYNZ EPS of $-2.86 for the current fiscal year, based on estimates from 1 analysts. The MYNZ revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MYNZ stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MYNZ price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The MYNZ short-term stock prediction for tomorrow is $2.33 (+0.09%).
Mainz Biomed B.V. trades on NASDAQ under the ticker MYNZ. The MYNZ stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
MYNZ forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month MYNZ price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.33.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.